NAD+
Cellular fuel for energy, focus and recovery, an NAD+ protocol reviewed around your biomarkers.
Only
Compounded medication
What it is, in plain terms
NAD+ is a coenzyme present in every cell you have. It is the currency your mitochondria use to convert food into usable energy, and it is central to DNA repair. Circulating levels fall measurably with age.
Injectable NAD+ bypasses the digestive breakdown that limits oral precursors. Patients most often describe the effect as recovered baseline energy and mental clarity rather than stimulation.
NAD+ is a coenzyme central to how your cells produce energy and repair themselves; levels decline with age. A monitored protocol supports mitochondrial function.
What is included
- Compounded NAD+ protocol
- Provider oversight & secure messaging
- Quarterly biomarker review
- Recovery guidance
What to expect
No. Patients typically describe steadier energy through the afternoon and clearer thinking, not a stimulant peak. If you are looking for an immediate lift, this is the wrong tool.
Most report a noticeable difference between weeks two and six. Benefit accumulates with consistent use, which is why interrupted dosing tends to disappoint.
Oral NAD+ is largely broken down before absorption, so most supplements use precursors instead. Subcutaneous injection delivers the molecule directly.
Yes, and it is one of our most common pairings, patients in a calorie deficit often want the energy support. Your provider confirms it for your history.
Mild flushing, a warm sensation, or transient injection-site tenderness are the usual reports. They typically settle within the first few doses.
Draft clinical copy, pending review by Dr. Kelm and the team before launch.
The titration plan was clearly explained and my provider actually responded when I had questions, steady, real progress.
No guesswork. Labs reviewed, dose adjusted, shipped discreetly. Exactly the clinical rigor I was looking for.
Felt like real medical care, not a vending machine. The follow-ups made the difference for me.
